MHUA vs. AKLI, SSKN, PAVM, MBOT, PETV, PYPD, NEPH, GCTK, TTOO, and NXGL
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include Akili (AKLI), STRATA Skin Sciences (SSKN), PAVmed (PAVM), Microbot Medical (MBOT), PetVivo (PETV), PolyPid (PYPD), Nephros (NEPH), GlucoTrack (GCTK), T2 Biosystems (TTOO), and NEXGEL (NXGL). These companies are all part of the "surgical & medical instruments" industry.
Meihua International Medical Technologies (NASDAQ:MHUA) and Akili (NASDAQ:AKLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Meihua International Medical Technologies has higher revenue and earnings than Akili.
Akili has a consensus target price of $4.00, indicating a potential upside of 1,776.17%. Given Akili's higher probable upside, analysts clearly believe Akili is more favorable than Meihua International Medical Technologies.
Meihua International Medical Technologies has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Akili has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Akili received 6 more outperform votes than Meihua International Medical Technologies when rated by MarketBeat users.
1.2% of Meihua International Medical Technologies shares are held by institutional investors. Comparatively, 53.1% of Akili shares are held by institutional investors. 66.6% of Meihua International Medical Technologies shares are held by company insiders. Comparatively, 10.1% of Akili shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Meihua International Medical Technologies has a net margin of 0.00% compared to Akili's net margin of -3,545.47%. Meihua International Medical Technologies' return on equity of 0.00% beat Akili's return on equity.
In the previous week, Akili's average media sentiment score of 1.00 beat Meihua International Medical Technologies' score of -1.00 indicating that Akili is being referred to more favorably in the news media.
Summary
Akili beats Meihua International Medical Technologies on 7 of the 13 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MHUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Meihua International Medical Technologies Competitors List
Related Companies and Tools